Program
Immune Globulin Subcutaneous Human
Its studies are mostly in Agammaglobulinemia · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, led by Grifols.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grifols | 22 open or running | phase 3since Dec 1, 2022 | Dec 1, 2022 | Dec 31, 2027phase 3 · NCT07540221 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2022First study: phase 3 study in AgammaglobulinemiaFirst studyNCT05645107 · 386 planned · United States, Bosnia and Herzegovina, Bulgaria and more
- Apr 9, 2026Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07540221 · 40 planned · United States, Czechia, Poland and more
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07540221
- Aug 2029Primary completion: phase 3 study in AgammaglobulinemiaNCT05645107
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07540221Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Czechia, Poland and more | 3 | Recruiting | Dec 31, 2027 | 40 |
| NCT05645107Agammaglobulinemia · United States, Bosnia and Herzegovina, Bulgaria and more | 3 | Recruiting | Aug 2029 | 386 |
How it is read
Names in the registry
- “Xembify”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.